title: AL vs. AH R4

description: Four arrays are included in one slide


title: BC vs. BL R1

status: Public on Aug 03 2010

type: RNA

city: College Station

first: Huaijun

last: Zhou

state: TX

address: Rm 418D Kleberg Center,Texas A&M University

country: USA

institute: Texas A&M University

description: Four arrays are included in one slide

hyb_protocol: A 825 ng of labeled cRNA with specificity over 8 were used for the hybridization reaction using the in situ hybridization kit plus (Agilent Technologies). A 100 ul hybridization solution was loaded on each of array in Agilent 4x44K microarrays. Arrays were incubated at 65 ℃ for 17h in Agilent’s microarray hybridization chambers. After hybridization, arrays were washed according to the Agilent protocol.

scan_protocol: Slides were scanned at 5-μm resolution using GenePix Personal 4100A (Molecular Devices Corporation, Sunnyvale, CA) and were saved as TIFF images. Auto Photomultiplier tube (PMT) were selected and adjusted to get the ratio of the overall intensities between the two channels (Cy3 and Cy5) was 0.9~1.1. The intensities of the spots on each image were quantified by Genepix pro 6.0 software (Molecular Devices Corporation, Downingtown, PA), and data were saved as .txt files for further analyses.

data_processing: The signal intensity of each gene was globally normalized using LOWESS by R program

molecule: total RNA

organism: Gallus gallus

source_name: Cecal tonsil

label_protocol: A 500 ng of aliquot of total RNA was reverse transcribed into cDNA using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). The synthesized cDNA was transcribed into cRNA labeled with one of two cyanine-labeled nucleotides (Perkin Elmer, Wellesley, MA). Labeled cRNA was purified with RNeasy Mini columns (Qiagen, Valecia, CA). The quality of each cRNA sample was verified by total yield and specificity measured with ND-100 spectrophotometer (NanoDrop Technologies).

growth_protocol: Raised on the floor in isolated room

extract_protocol: Cecal tonsil was homogenized by tissue miser (Fisher Scientific, Houston, TX). Total RNA was isolated using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA).

treatment_protocol: Orally inoculated with PBS on one day after hatch

tag: Broiler

tag: one week

tag: control

treatment_protocol: Orally inoculated with 10^5 cfu C. jejuni on one day after hatch

tag: low C. jejuni burden


title: AH vs. AC R4

description: Four arrays are included in one slide

tag: High C. jejuni burden

tag: Control


title: AC vs. AL R4

description: Four arrays are included in one slide

tag: control group


title: doxorubicin treated,collect RNA at day 7 ,rep2

city: Tainan city

first: Jimmy

middle: Jiun-Ming

last: Su

address: 1F,No 367,Sheng-Li Rd. North District

department: National Institute of Cancer Research

country: Taiwan

institute: National Health Research Institutes,Taiwan

hyb_protocol: Following fragmentation, 15 ug of cRNA were hybridized for 16 hr at 45C on Affymetrix Human Genome U133 Plus 2.0 GeneChip. GeneChips were washed and stained in the GeneChip®Fluidics Station 450.

scan_protocol: GeneChips were scanned using the GeneChip®Scanner 3000.

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method.

label: biotin

organism: Homo sapiens

source_name: Breast associatd fibroblasts

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 0.1ug total RNA (Genechip 3'-IVT express kit, Affymetrix).

growth_protocol: The BCAFs were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics

extract_protocol: Total RNA samples were extracted from doxorubicin- , paclitaxel- or vehicle-treated breast CAFs using TRIZOL (Sigma) and then purified using an RNeasy mini-kit and a DNase treatment (Qiagen).

treatment_protocol: Early-passage (passage 4-6) breast CAFs were treated with doxorubicin (Sigma) at 50 nM for 96 hours or paclitaxel (Sigma) at 0.65 μM for 24 hours.  After completion of the treatments the cells were washed twice with PBS, replenished with drug-free culture medium and the cultures were maintained until subsequent analysis.

tag: age

value: 59 years old

tag: tissue

value: Breast

tag: cell type

value: Breast cancer associated fibroblasts (BCAFs)

tag: agent

value: Doxorubicin

tag: time

value: day 7


title: AC vs. AL R2

description: Four arrays are included in one slide

tag: One week

treatment_protocol: Orally inoculated with 10^5 C. jejuni on one day after hatch

tag: Low C. jejuni burden


title: AH vs. AC R2

description: Four arrays are included in one slide

tag: high C. jejuni burden


title: doxorubicin treated,collect RNA at day 7 ,rep1


title: AC vs. AL R3

description: Four arrays are included in one slide

tag: low C.jejuni burden


title: AH vs. AC R1

description: Four arrays are included in one slide

growth_protocol: The chickens were raised on the floor in isolated room.

treatment_protocol: The chicken was inoculated with 10^5 cfu C. jejuni at one day after hatch

treatment_protocol: The chicken was inoculated with PBS as control at one day after hatch

tag: Control group


title: doxorubicin treated,collect RNA at day 3 ,rep2

value: day 3


title: AL vs. AH R2

description: Four arrays are included in one slide

tag: Broiler

growth_protocol: Raised on the floor in the isolated room


title: AL vs. AH R1

description: Four arrays are included in one slide


title: AC vs. AL R1

description: Four arrays are included in one slide

treatment_protocol: The chicken was inoculated with PBS as control group at one day after hatch


title: doxorubicin treated,collect RNA at day 1 ,rep1

value: day 1


title: AL vs. AH R3

description: Four arrays are included in one slide

tag: one week


title: paclitaxol treated,collect RNA at day 3 ,rep2

value: Paclitaxol


title: doxorubicin treated,collect RNA at day 1 ,rep2


title: BL vs. BH R1

description: Four arrays are included in one slide

source_name: cecal tonsil


title: paclitaxol treated,collect RNA at day 7 ,rep2


title: paclitaxol treated,collect RNA at day 1 ,rep2


title: doxorubicin treated,collect RNA at day 3 ,rep1


title: no treatment , biological rep2

value: Vehicle

value: control


title: paclitaxol treated,collect RNA at day 3 ,rep1


title: no treatment , biological rep1


title: USSC day 6

city: Nijmegen

first: Ruurd

last: Torensma

address: GeertGrooteplein 28

department: Tumorimmunology

country: Netherlands

institute: Radboud University Nijmegen Medical Centre

description: Unrestricted Somatic Stem Cells (USSC)

hyb_protocol: 17 hours at 45 degrees in Affymetrix hybridization oven at 60 rpm,washing and staining in Fluidics station 450 using stain cocktails: SAPE and antibody solution, (protocol FS450_0001)

scan_protocol: GeneChip scanner 3000 7G

data_processing: RMA + GC correction, normalized to the median and log10 transformed using Agilent GeneSpring v7.3 software

source_name: Human cord blood

label_protocol: GeneChip WT Terminal Labeling Kit

growth_protocol: Cultured in Low Glucose DMEM, 30% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM ultraglutamine

extract_protocol: RNeasy column purification

value: cord blood

value: Unrestricted Somatic Stem Cells (USSC)


title: paclitaxol treated,collect RNA at day 1 ,rep1


title: paclitaxol treated,collect RNA at day 7 ,rep1


title: HeLa cells, mock-transfected, 32hr

city: Singapore

first: Huili

last: Guo

address: 28 Medical Drive

country: Singapore

institute: National University of Singapore

hyb_protocol: Biotinylated cRNA was hybridized at the Whitehead Institute Genome Technology Core, according to standard Affymetrix protocols.

scan_protocol: Arrays were stained, scanned, and quantified according to standard Affymetrix protocols.

data_processing: Raw data was normalized using the RMAExpress software.

source_name: HeLa cells, mock-transfected, 32hr

label_protocol: Biotinylated cRNA were prepared according to the Affymetrix 3' IVT Express Kit manual.

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions.

treatment_protocol: All samples were treated with cycloheximide (100 ug/ml) for 8 min just before harvesting.

tag: transfection

value: mock


title: HeLa cells, transfected with miR-155 duplex, 32hr

value: miR-155 duplex


title: HeLa cells, transfected with miR-155 duplex, 12hr


title: HNEC cells incubated with 50µM FA  4 times, biological rep3

city: Ulm

first: Karlheinz

last: Holzmann

address: Helmholtzstreet 8/1

department: Medical Faculty

country: Germany

institute: Ulm University

hyb_protocol: according to Affymetrix

scan_protocol: according to Affymetrix

data_processing: The data were analyzed with BRB Array Tools

label_protocol: One Cycle Target Labelling Protocol

extract_protocol: Rneasy Mini Kit, Qiagen

value: nasal epithelial cell

tag: treatment

value: incubated with 50µM FA  4 times


title: HNEC cells incubated with 50µM FA  4 times, biological rep2


title: HeLa cells, transfected with miR-1 duplex, 32hr

value: miR-1 duplex


title: USSC+DC day 6

description: Unrestricted Somatic Stem Cells (USSC) co-cultured with Dendritic cells


title: HNEC cells incubated with 100µM FA for 4 hours, biological rep3

value: incubated with 100µM FA for 4 hours


title: HeLa cells, transfected with miR-1 duplex, 12hr


title: HNEC cells incubated with 200µM FA for 24 hours, biological rep3

value: incubated with 200µM FA for 24 hours


title: HNEC cells control group after 4 hours, biological rep3

value: control group after 4 hours


title: HeLa cells, mock-transfected, 12hr

source_name: HeLa cells, mock-transfected, 12hr


title: HNEC cells control group after 24 hours, biological rep3

value: control group after 24 hours


title: HNEC cells incubated with 20µM FA  4 times, biological rep2

value: incubated with 20µM FA  4 times


title: HNEC cells control group FA 4 times, biological rep1

value: control group


title: HNEC cells control group FA 4 times, biological rep3


title: HNEC cells control group FA 4 times, biological rep2


title: HNEC cells incubated with 100µM FA for 24 hours, biological rep3

value: incubated with 100µM FA for 24 hours


title: HNEC cells incubated with 20µM FA  4 times, biological rep1


title: HNEC cells incubated with 200µM FA for 4 hours, biological rep2

value: incubated with 200µM FA for 4 hours


title: HNEC cells incubated with 200µM FA for 4 hours, biological rep3


title: HNEC cells incubated with 20µM FA  4 times, biological rep3


title: HNEC cells control group after 24 hours, biological rep1


title: HNEC cells incubated with 100µM FA for 24 hours, biological rep2


title: HNEC cells control group after 4 hours, biological rep2


title: HNEC cells incubated with 100µM FA for 4 hours, biological rep2


title: HNEC cells incubated with 200µM FA for 24 hours, biological rep2


title: HNEC cells incubated with 200µM FA for 24 hours, biological rep1


title: HNEC cells control group after 24 hours, biological rep2


title: HNEC cells incubated with 50µM FA  4 times, biological rep1


title: HNEC cells control group after 4 hours, biological rep1


title: HNEC cells incubated with 200µM FA for 4 hours, biological rep1


title: HNEC cells incubated with 100µM FA for 24 hours, biological rep1


title: HNEC cells incubated with 50µM FA for 4 hours, biological rep2

value: incubated with 50µM FA for 4 hours


title: HNEC cells incubated with 100µM FA for 4 hours, biological rep1


title: HNEC cells incubated with 100µM FA for 2 hours, biological rep3

value: incubated with 100µM FA for 2 hours


title: HNEC cells control group, biological rep2


title: HNEC cells incubated with 50µM FA for 2 hours, biological rep2

value: incubated with 50µM FA for 2 hours


title: HNEC cells incubated with 50µM FA for 4 hours, biological rep3


title: HNEC cells control group, biological rep1


title: HNEC cells incubated with 100µM FA for 2 hours, biological rep2


title: HNEC cells incubated with 50µM FA for 4 hours, biological rep1


title: HNEC cells control group, biological rep3


title: Neutrophils cultured from wild-type mouse bone marrow

organism: Mus musculus

growth_protocol: Haematopoietic progenitors were isolated from wild-type and mir-223 knockout male mice and cultured in media containing granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) for six days before harvesting.

tag: strain

tag: genotype

value: wild-type


title: HNEC cells incubated with 100µM FA for 2 hours, biological rep1


title: Neutrophils cultured from  mir-223 knockout mouse bone marrow

value: mir-223 knockout


title: HNEC cells incubated with 50µM FA for 2 hours, biological rep1


title: Normal spermatogonia control, rep2

city: Bethesda

first: TIN-LAP

last: LEE

state: MD

address: 2C08 Building 49

department: NICHD

institute: National Institutes of Health

description: Gene expression data from normal spermatogonia.

hyb_protocol: Following fragmentation, 12.5 ug of cDNA were hybridized for 16 hr at 45C on the GeneChip Mouse Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.

scan_protocol: GeneChips were scanned using the Affymetrix Scanner G3000 7G.

data_processing: Raw expression values in Affymetrix CEL file format were generated by GeneChip Operating Software. The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100.

label: Biotin

source_name: Normal spermatogonia

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix two-cycle amplification protocol from 100ng total RNA.

extract_protocol:
Spermatogonia were isolated by the STATPUT procedure. Decapsulated testes from 2 mice were suspended in RPMI medium containing collagenase (0.6 mg/ml), Hyaluronidase (0.12 mg/ml) and DNAse I (1.25 mg/ml) and incubated at 37ºC for 30 minutes in a shaking water bath. The tissues were then allowed to come down the tube and the supernatant (containing interstitial cells) was removed. The pellet was incubated with 3 ml of 0.25% Trypsin /EDTA in the presence of DNAse I (0.2 mg/ml) at 37ºC for 15 minutes in a shaking water bath. The dispersed cells were washed twice with RPMI medium containing 10% heat-inactivated FBS to neutralize the protease activity, and filtered through a sterile 0.22 nylon to remove any undigested fragments. Cells of the dissociated seminiferous epithelium were then plated overnight in a 34ºC 3% CO2 incubator. The following day, germ cells, in suspension, were separated by sedimentation with use of a 2-4% BSA gradient. The cells were allowed to sediment for a standard period of 2.5 h, and fractions of 2-ml volume were collected. The cells of each fraction were examined under a phase contrast microscope, and fractions containing cells of similar size and morphology were pooled and spun down by low-speed centrifugation. Purity of spermatogonia was estimated and was routinely higher than 90%.

Total RNA was extracted from the isolated germ cells using TRIzol Reagent and cleaned with RNeasy mini-columns.

treatment_protocol: Mice were fed a control or VAD diet. Spermatogonial stem cells were selected from animals at 18 and 25 weeks of VAD. The vitamin A status of the mice was determined by measurement of serum RBP levels using the Dual Mouse/Rat RBP4 EIA Kit.

value: Balb/C

tag: developmental stage

value: adult

value: testes

value: spermatogonia

value: normal diet


title: VAD spermatogonia at 25 weeks, rep2

description: Gene expression data from VAD spermatogonia at 25 weeks.

source_name: VAD spermatogonia at 25 weeks

value: vitamin A-deficient diet

tag: treatment time

value: 25 weeks


title: VAD spermatogonia at 18 weeks, rep2

description: Gene expression data from VAD spermatogonia at 18 weeks.

source_name: VAD spermatogonia at 18 weeks

tag: tissue

value: 18 weeks


title: Normal spermatogonia control, rep3

tag: cell type


title: Normal spermatogonia control, rep1


title: VAD spermatogonia at 18 weeks, rep3


title: glomerulus_transgenic_biological replicate 3

city: Kansas City

first: Brooke

middle: M

last: Steenhard

state: KS

address: 3901 Rainbow Blvd

department: Anatomy and Cell Biology

institute: Univ of KS Medical Center

hyb_protocol: Following fragmentation, 15 ug of cRNA were hybridized for 16 hr at 45C on GeneChip® Mouse Genome 430 2.0 Array.  GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: Single scans were performed using the Affymetrix GeneChip 3000 scanner

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS5.0) on Affymetrix Data Mining Tool using Affymetrix default analysis settings as normalization method. http://www.affymetrix.com/support/technical/manual/expression_manual.affx

source_name: glomerulus transgenic podocin-Cre excision of von Hippel-Lindau

label_protocol: Biotinylated cRNA were prepared using Affymetrix GeneChip IVT Labeling kit according to the manufacturer’s instructions.

growth_protocol: Phenotyping protocol Litters were generated by crossing mice carrying both a single copy of Pod-Cre transgene (Moeller MJ et al., Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 2003, 35(1):39-42) and homozygous for a floxed-modified von Hippel-Lindau locus (Haase VH et al.,Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.  Proc Natl Acad Sci U S A 2001 98(4):1583-1588).  Urine was sampled by passive collection and a 6 microliter sample was separated on SDS-PAGE gel and stained with Commassie blue.  Urine was diluted, based on SDS-PAGE results, and quantified by Exocell mouse albumin elisa.  Animals were selected for the study with the Pod-Cre+ fVHL genotype and albumin levels ≤ the average of wildtype littermates.

extract_protocol: Total glomerular RNA was isolated using Qiagen RNeasy spin columns according to the manufacturer’s instructions.

treatment_protocol: Three Pod-Cre fVHL mice and three littermate controls were selected for glomerular isolation using the magnetic bead technique (Takemoto M., et al., A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002, 161(3):799-805).  Isolated glomeruli were washed three times with Hanks balanced salt solution, pelleted, flash frozen on dry ice and stored at -80oC until RNA isolation.

tag: genotype/variation

tag: gender

value: female

tag: age

value: 6 weeks

value: glomerular isolation using magnetic bead perfusion


title: VAD spermatogonia at 18 weeks, rep1


title: zebrafish_han_Mut_Rep3

city: La Jolla

first: Zayra

middle: Viviana

last: Garavito-Aguilar

state: CA

address: 9500 Gilman Drive #0347

department: Division of Biological Sciences

institute: University of California, San Diego

hyb_protocol: Affymetrix standard protocol

scan_protocol: According to manufacturer

data_processing: MAS5, overall intensity was targetted to 500

organism: Danio rerio

source_name: hand2 mutant sibling,19hpf

label_protocol: ambion megascript labeling, with biotin labeled dNTP

growth_protocol: Embryos were collected, grown in blue water (60 mg/mL Instant Ocean and 0.025% Methylene blue) at 28.5 degrees Celcius and dechorionated prior to RNA extraction

extract_protocol: 3-9mg of total RNA from 10 to 25 embryos per sample were isolated using the RNeasy kit (Qiagen) according to manufacturer's instructions.

tag: stage

value: 19 hpf

value: Whole embryo


title: VAD spermatogonia at 25 weeks, rep1


title: glomerulus_wildtype_biological replicate 2

source_name: glomerulus wildtype control

value: wildtype control


title: zebrafish_han_Mut_Rep2


title: VAD spermatogonia at 25 weeks, rep3


title: glomerulus_transgenic_biological replicate 1

value: transgenic podocin-Cre excision of von Hippel-Lindau


title: Karyotyping of EC haploid strains (S. cerevisiae)

type: genomic

city: Taipei

first: Jun-Yi

last: Leu

address: 128 Academia Road, Section 2, Nankang

department: Insititute of Molecular Biolody

institute: Academia Sinica

description: The karyotype of EC9 haploid segregants(EC9-5) which was analyzed by array-CGH to identify amplified chromosomal regions.

hyb_protocol: The hybridization protocol was adapted from Microarray Core Facility, Insititute of Molecular Biology, Academia Sinica, TW (http://www.imb.sinica.edu.tw/mdarray/methods.html)

scan_protocol: Scanned on an Molecular Device AXON 4000B (version GenePix 6.0) and got .gpr files

data_processing: Subtracted background. Dividing by ch2 (control) was used to transform data (Agilent GeneSpring 7.3.1 software)

molecule: genomic DNA

organism: Saccharomyces cerevisiae

source_name: EC9-7 haploid strain

label_protocol: The label protocol was adapted from Microarray Core Facility, Insititute of Molecular Biology, Academia Sinica, TW (http://www.imb.sinica.edu.tw/mdarray/methods.html)

growth_protocol: Grow in YPD medium

extract_protocol: Yeast genomic DNA was extracted using QIAGEN Genomic-tip 100/G kit

value: EC9-7 haploid strain (JYL2155), the haploid segregant of EC9

source_name: w303 haploid strain, control

value: w303 haploid strain (JYL1127)


title: zebrafish_han_Mut_Rep1


title: Karyotyping of EC diploid strains (S. cerevisiae)

description: The EC9(diploid) strain karyotype was analyzed by array-CGH to identify amplified chromosomal regions.

source_name: EC9 diploid strain

value: EC9 diploid strain (JLD78)

source_name: w303 diploid strain, control

value: w303 diploid strain (JYL1127 X JYL1128)


title: pRAD7 Δrad23 60, biological rep2

status: Public on Aug 02 2010

city: CARDIFF

first: Simon

last: Reed

address: Heath Park

department: School of Medicine

country: United Kingdom

institute: Cardiff University

description: Microarray experiments were performed using a yeast S98 chip oligonucleotide array (Affymetrix, Inc.) according to the manufacturer's instructions (http://www.affymetrix.com/support/technical/manuals.affx). Approximately 1 µg of total RNA was processed into biotinylated cRNA according to Affymetrix protocols; 15-µg biotinylated cRNA targets were fragmented and hybridized to the arrays at 45°C for 16 h. The arrays were then processed using Affymetrix fluidics protocol EukGE-WS2 (V4 450) and stained with R-phycoerythrin conjugated to streptavidin (Molecular Probes, Inc). Microarray images were acquired using the 2500 GeneChip scanner (Affymetrix) and GCOS software. Expression summarization was undertaken using the MAS 5.0 algorithm in Affymetrix Expression Console.

hyb_protocol: Eukaryotic Target preparation Manual. 15-µg biotinylated cRNA targets were fragmented and hybridized to the arrays at 45°C for 16 h. The arrays were then processed using Affymetrix fluidics protocol EukGE-WS2 (V4 450) and stained with R-phycoerythrin conjugated to streptavidin (Molecular Probes, Inc).

scan_protocol: Eukaryotic Target preparation Manual. Microarray images were acquired using the 2500 GeneChip scanner (Affymetrix) and GCOS software.

source_name: pRAD7 Δrad23 Strain 60 minutes Post-UV

label_protocol: Affymetrix Genechip Expression Amplification one-cycle target labeling reagents.  Approximately 1 µg of total RNA was processed into biotinylated cRNA according to Affymetrix protocols.

growth_protocol: Cells grown to late log phase at 30°C in HIS- SC-Minimal Medium

treatment_protocol: UV-treatment where stated with 100Jm-2 in SC-Minimal Media using a 254nm Germicidal UV Lamp (delivered at 10Jm-2s-1)

value: rad23::URA3 pRS313-RAD7

tag: stress

value: UV

tag: time

value: 60 minutes


title: pRAD7 Δrad23 60, biological rep1

data_processing: Expression summarization was undertaken using the MAS 5.0 algorithm in Affymetrix Expression Console.


title: zebrafish_han_WT_Rep2

source_name: hand2 wild-type sibling,19hpf


title: psocs Δrad23 60, biological rep1

source_name: psocs Δrad23 Strain 60 minutes Post-UV

value: rad23::URA3 pRS313-socs


title: zebrafish_han_WT_Rep3


title: glomerulus_transgenic_biological replicate 2


title: psocs Δrad23 60, biological rep2


title: glomerulus_wildtype_biological replicate 3


title: pRAD7 60, biological rep3

source_name: pRAD7 Strain 60 minutes Post-UV


title: psocs 60, biological rep3

source_name: psocs Strain 60 minutes Post-UV


title: pRAD7 60, biological rep2


title: zebrafish_han_WT_Rep1


title: psocs 15, biological rep3

source_name: psocs Strain 15 minutes Post-UV

value: 15 minutes


title: glomerulus_wildtype_biological replicate 1


title: pRAD7 Δrad23 15, biological rep1

source_name: pRAD7 Δrad23 Strain 15 minutes Post-UV


title: psocs 60, biological rep1


title: pRAD7 Δrad23 15, biological rep2


title: pRAD7 60, biological rep1


title: psocs 15, biological rep1


title: pRAD7 15, biological rep1

source_name: pRAD7 Strain 15 minutes Post-UV


title: Cdc73_ChIP

city: Boston

first: Xiaoying

last: Bai

state: MA

address: 1 Blackfan Circle

institute: Children's Hospital Boston

description: Three biologcal repeats were performed. Data are generated by comparing TIF1g-ChIP with Mock-ChIP.

hyb_protocol: Microarray hybridization was performed at Microarray Core   Facility - Dana-Farber Cancer Institute.

scan_protocol: Scanning were performed at Microarray Core   Facility - Dana-Farber Cancer Institute.

data_processing: MAT (Model-based Analysis of Tiling-array)   was applied to predict the target loci, and targets were predicted at   the MAT with p-value=1.00E-6.

source_name: cdc73 ChIP DNA

label_protocol: ChIP samples were amplified by ligation-mediated PCR (LM-PCR). DNA fragmentation and biotin labeling steps were performed according to the manufacturer’s instructions.

growth_protocol: IMDM medium + 2% pen-strep +10% FCS

extract_protocol: ~ 5 × 107 K562 cells were used for each ChIP reaction using a standard ChIP protocal. Briefly, cells were cross-linked by addition of final 1%   formaldehyde for 7 min at room temperature. Cross-linking was terminated by adding   final 125 mM glycine and cells were washed with cold phosphate-buffered saline (PBS)   collected by centrifugation and washed again. Collected cell pellet was resuspended in SDS ChIP buffer (0.1% SDS, 1% Triton X-100,   2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM NaCl, and protease inhibitors). Cells   were sonicated and fragmented DNA was visualized on an agarose gel (average size   0.5-1 kb). The sample was centrifuged at 12000 rpm at 4°C for 10 min and supernatant was collected. Sample was pre-cleared with protein A beads at 4°C for 1 hr and  incubated with with 1:100 dilution of antibod. Immunoprecipitated complexes were successively   washed with buffer I (2% SDS), buffer II (0.1% Deoxycholate, 1% Triton X-100, 1 mM   EDTA, 50 mM HEPES pH 7.5, 500 mM NaCl), buffer III (250 mM LiCl, 0.5% NP-40,   0.5% Deoxycholate, 1 mM EDTA, 10 mM Tris-Cl pH 8.1) and TE buffer (10 mM Tris-   Cl pH 7.5, 1 mM EDTA). All washes were for 8 min at room temperature. SDS elution   buffer was added and incubated at 65°C overnight to reverse crosslink protein-DNA   complexes. The sample was treated with RNase A and Proteinase K, extracted with   phenol:chloroform and precipitated. The pellet was resuspended in 25μl of water.

tag: antibody

tag: cell line

value: k562 erythroleukemia cell

source_name: Mock-ChIP DNA (no antibody)

tag: reference

value: input


title: psocs Δrad23 15, biological rep2

source_name: psocs Δrad23 Strain 15 minutes Post-UV


title: TIF1g_ChIP

source_name: TIF1g ChIP DNA


title: psocs Untreated, biological rep3

source_name: psocs Strain Untreated

value: untreated

value: control


title: psocs Δrad23  Untreated, biological rep2

source_name: psocs Δrad23 Strain Untreated


title: pRAD7 15, biological rep3


title: pRAD7 Δrad23  Untreated, biological rep2

source_name: pRAD7 Δrad23 Strain Untreated


title: pRAD7 Δrad23  Untreated, biological rep1


title: psocs Δrad23 15, biological rep1


title: psocs Untreated, biological rep2


title: psocs 15, biological rep2


title: psocs Δrad23  Untreated, biological rep1


title: psocs Untreated, biological rep1


title: pRAD7 15, biological rep2


title: pRAD7 Untreated, biological rep1

source_name: pRAD7 Strain Untreated


title: HNEC cells incubated with 50µM FA for 2 hours, biological rep3

value: nasal epithelial cell

value: incubated with 50µM FA for 2 hours


title: pRAD7 Untreated, biological rep2


title: pRAD7 Untreated, biological rep3


title: Clear cell renal cell carcinoma (ccRCC)

city: Duarte

first: Robin

address: 1500 E. Duarte Rd.

department: Molecular Pharmacology

institute: City of Hope

description: Extracted ccRCC DNA sample was compared to normal human control DNA sample.

hyb_protocol: Genomic DNA was hybridized to Agilent CGH arrays as per manufacturer’s protocol (Agilent Technologies Version 3.1 August 2009, Santa Clara CA, http://www.agilent.com).

scan_protocol: Scanning for 244k arrays was performed following manufacturer's protocol (Agilent Technologies Version 3.1 August 2009, Santa Clara CA, http://www.agilent.com).

data_processing: Log2 (test/reference) ratio data are background subtracted and Lowess-normalized in R. Further processed in Nexus copy number software.

source_name: ccRCC

label_protocol: The Agilent Genomic DNA ULS labeling kit for 244k arrays was used as per manufacturer's protocol (Agilent Technologies Version 3.1 August 2009, Santa Clara CA, http://www.agilent.com).

extract_protocol: DNA was extracted from formalin-fixed paraffin embedded tissue using WaxFree DNA extraction kit following manufacturer's instructions (Trimgen, Sparks MD, http://www.trimgen.com).

value: male

value: 74 years

value: clear cell renal cell carcinoma

source_name: Normal Human DNA Control

extract_protocol: Normal human genomic DNA was extracted from saliva using Oragene DNA extraction kit following manufacturer's instructions (DNA Genotek, Ontario Canada, http://www.dnagenotek.com).

value: 23 years

value: saliva

tag: disease state

value: healthy


title: Mantle cell lymphoma (MCL)

description: Extracted MCL DNA sample was compared to normal human control DNA sample.

source_name: MCL

value: mantle cell lymphoma


title: HF-23846-(1)

status: Public on Jul 29 2010

city: South San Francisco

first: Peter

last: Haverty

address: 1 DNA Way

department: Bioinformatics

institute: Genentech, Inc.

description: Tumor vs. Normal.

hyb_protocol: Agilent's Oligonucleotide Array-Based CGH for Genomic DNA Analysis protocol.

scan_protocol: Agilent's user manual (Agilent scanner).

data_processing: Tumor samples were assayed on Agilent Human Genome CGH 244A Microarrays. Human male genomic DNA (Promega P/N G1471) was used as reference.  Individual log2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log2 ratios were centered to a median of zero and the resulting log2 ratio values for each probe were segmented using GLAD [3]. All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment.

source_name: lung cancer, HF-23846-(1)

label_protocol: Agilent's Genomic DNA Labeling Kit Plus.

extract_protocol: Qiagen Allprep extraction kit was used according to the manufacturer's instructions.

tag: sampleID

tag: sourceID

value: lung cancer

tag: cancer subtype

value: carcinoma squamous cell

source_name: male genomic DNA

extract_protocol: Reference male genomic DNA was obtained from Promega (P/N G1471).

tag: sample type

value: reference


title: HF-23898-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23898-(1)


title: HF-23848-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23848-(1)


title: HF-23800-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23800-(1)


title: psocs 60, biological rep2

source_name: psocs Strain 60 minutes Post-UV

tag: strain

value: UV

value: 60 minutes


title: Gastrointestinal stromal tumor (GIST)

description: Extracted GIST DNA sample was compared to normal human control DNA sample.

source_name: GIST

tag: tissue

value: gastrointestinal stromal tumor


title: HF-23838-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23838-(1)


title: HF-23836-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23836-(1)


title: HF-23856-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23856-(1)


title: HF-23790-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23790-(1)


title: HF-23828-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23828-(1)


title: HF-23894-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23894-(1)


title: HF-23906-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23906-(1)


title: HF-23797-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23797-(1)


title: HF-23805-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23805-(1)


title: HF-23840-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23840-(1)


title: HF-23890-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23890-(1)

value: adenocarcinoma


title: HF-23896-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23896-(1)

source_name: male genomic DNA


title: HF-23815-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23815-(1)


title: HF-23869-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23869-(1)


title: HF-23803-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23803-(1)

value: others


title: HF-23900-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23900-(1)


title: HF-23819-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23819-(1)


title: HF-23787-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23787-(1)


title: HF-23826-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23826-(1)


title: HF-23834-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23834-(1)


title: HF-23772-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23772-(1)


title: HF-23776-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23776-(1)


title: HF-23770-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23770-(1)


title: HF-23784-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23784-(1)


title: HF-20972-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20972-(1)


title: HF-23792-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23792-(1)


title: HF-23794-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23794-(1)


title: HF-20970-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20970-(1)


title: HF-20978-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20978-(1)

source_name: male genomic DNA


title: HF-23809-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-23809-(1)


title: HF-20683-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20683-(1)


title: HF-20689-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20689-(1)


title: HF-20132-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20132-(1)


title: HF-19985-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19985-(1)


title: HF-20703-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20703-(1)


title: HF-20665-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20665-(1)


title: HF-20136-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20136-(1)


title: HF-20313-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20313-(1)


title: HF-19957-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19957-(1)


title: HF-19979-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19979-(1)


title: HF-19933-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19933-(1)


title: HF-16449-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-16449-(1)


title: HF-24193-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24193-(1)

value: ovarian cancer


title: HF-19951-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19951-(1)


title: HF-20976-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20976-(1)


title: HF-24157

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24157

source_name: male genomic DNA


title: HF-24175

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24175


title: HF-20148-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-20148-(1)


title: HF-19975-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19975-(1)


title: HF-19941-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19941-(1)


title: HF-24234-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24234-(1)


title: HF-24236-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24236-(1)


title: HF-19963-(1)

description: Tumor vs. Normal.

source_name: lung cancer, HF-19963-(1)


title: HF-24230-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24230-(1)


title: HF-24222-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24222-(1)


title: HF-23932-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23932-(1)


title: HF-24224-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24224-(1)


title: HF-23930-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23930-(1)


title: HF-24218-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24218-(1)


title: HF-24184

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24184


title: HF-24228-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-24228-(1)


title: HF-23925-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23925-(1)


title: HF-23914-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23914-(1)

source_name: male genomic DNA


title: HF-23921-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23921-(1)


title: HF-21648-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21648-(1)


title: HF-23909-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23909-(1)


title: HF-21650-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21650-(1)


title: HF-21652-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21652-(1)


title: HF-23912-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23912-(1)


title: HF-21666-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21666-(1)


title: HF-21662-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21662-(1)


title: HF-22203-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-22203-(1)


title: HF-20994-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20994-(1)


title: HF-20901-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20901-(1)


title: HF-20933-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20933-(1)


title: HF-20927-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20927-(1)


title: HF-21298-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21298-(1)


title: HF-22133-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-22133-(1)


title: HF-20931-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20931-(1)


title: HF-21301-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21301-(1)

source_name: male genomic DNA


title: HF-20929-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20929-(1)


title: HF-22202-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-22202-(1)


title: HF-23911-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23911-(1)


title: HF-20996-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20996-(1)


title: HF-21664-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21664-(1)


title: HF-21300-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-21300-(1)


title: HF-22201-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-22201-(1)


title: HF-20889-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20889-(1)


title: HF-20925-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20925-(1)


title: HF-20917-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20917-(1)


title: HF-23923-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23923-(1)


title: HF-20757-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20757-(1)


title: HF-18768-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-18768-(1)


title: HF-20921-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20921-(1)


title: HF-19079-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-19079-(1)


title: HF-24392-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24392-(1)

value: melanoma


title: HF-23918-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-23918-(1)

source_name: male genomic DNA

value: male


title: HF-18387-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-18387-(1)


title: HF-24410-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24410-(1)


title: HF-24386-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24386-(1)


title: HF-20923-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-20923-(1)


title: HF-24380-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24380-(1)


title: HF-24384-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24384-(1)


title: HF-24419-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24419-(1)


title: HF-24408-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24408-(1)


title: HF-22430-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22430-(1)


title: HF-19085-(1)

description: Tumor vs. Normal.

source_name: ovarian cancer, HF-19085-(1)


title: HF-22432-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22432-(1)


title: HF-24390-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24390-(1)


title: HF-22426-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22426-(1)


title: HF-24426-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24426-(1)


title: HF-24434-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24434-(1)


title: HF-24438-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24438-(1)


title: HF-24428-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24428-(1)

source_name: male genomic DNA


title: HF-24404-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24404-(1)


title: HF-22436-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22436-(1)


title: HF-22212-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22212-(1)


title: HF-22422-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22422-(1)


title: HF-24407-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24407-(1)


title: HF-22210-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22210-(1)


title: HF-22135-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22135-(1)


title: HF-22211-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22211-(1)


title: HF-24403-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24403-(1)


title: HF-24422-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24422-(1)


title: HF-22421-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22421-(1)


title: HF-22209-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22209-(1)


title: HF-21719-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21719-(1)


title: HF-21670-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21670-(1)


title: HF-20982-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20982-(1)


title: HF-21672-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21672-(1)


title: HF-21700-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21700-(1)

source_name: male genomic DNA


title: HF-21717-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21717-(1)


title: HF-21680-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21680-(1)


title: HF-20988-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20988-(1)


title: HF-21696-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21696-(1)


title: HF-20867-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20867-(1)


title: HF-21687-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21687-(1)


title: HF-20883-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20883-(1)


title: HF-20865-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20865-(1)


title: HF-20861-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20861-(1)


title: HF-24412-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24412-(1)


title: HF-21698-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21698-(1)


title: HF-20855-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20855-(1)


title: HF-21713-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21713-(1)


title: HF-20857-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20857-(1)


title: HF-24106-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24106-(1)

value: prostate cancer


title: HF-24100-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24100-(1)


title: HF-20986-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20986-(1)

source_name: male genomic DNA


title: HF-24331-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24331-(1)


title: HF-21702-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-21702-(1)


title: HF-20753-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-20753-(1)


title: HF-24108-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24108-(1)


title: HF-24098-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24098-(1)


title: HF-24102-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24102-(1)


title: HF-24388-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-24388-(1)


title: HF-24096-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24096-(1)


title: HF-24104-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24104-(1)


title: HF-24092-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24092-(1)


title: HF-22213-(1)

description: Tumor vs. Normal.

source_name: melanoma HF-22213-(1)


title: HF-24094-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24094-(1)


title: HF-24118-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24118-(1)


title: HF-24084-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24084-(1)


title: HF-24090-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24090-(1)


title: HF-24124-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24124-(1)


title: HF-24142-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24142-(1)

source_name: male genomic DNA


title: HF-24082-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24082-(1)


title: HF-24114-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24114-(1)


title: HF-24130-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24130-(1)


title: HF-24144-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24144-(1)


title: HF-24138-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24138-(1)


title: HF-24136-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24136-(1)


title: HF-24088-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24088-(1)


title: HF-24086-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24086-(1)


title: HF-24080-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24080-(1)


title: HF-24140-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24140-(1)


title: HF-24128-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24128-(1)


title: HF-24148-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24148-(1)


title: HF-24074-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24074-(1)


title: HF-24076-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24076-(1)


title: HF-24068-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24068-(1)


title: HF-24126-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24126-(1)


title: HF-24070-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24070-(1)

source_name: male genomic DNA


title: HF-24072-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24072-(1)


title: HF-24060-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24060-(1)


title: HF-24066-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24066-(1)


title: HF-24064-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24064-(1)


title: HF-24120-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24120-(1)


title: HF-24058-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24058-(1)


title: HF-24146-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24146-(1)


title: HF-24050-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24050-(1)


title: HF-24134-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24134-(1)


title: HF-24038-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24038-(1)


title: HF-24034-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24034-(1)


title: HF-23739-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23739-(1)


title: HF-24036-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24036-(1)


title: HF-23742-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23742-(1)


title: HF-23256-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23256-(1)


title: HF-23751-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23751-(1)


title: HF-22399-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-22399-(1)

source_name: male genomic DNA


title: HF-22102-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22102-(1)

value: breast cancer

value: Triple Neg


title: HF-24054-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-24054-(1)


title: HF-20561-(2)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20561-(2)


title: HF-22046-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22046-(1)


title: HF-22404-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-22404-(1)


title: HF-20224-(2)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20224-(2)


title: HF-23762-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23762-(1)


title: HF-23262-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23262-(1)


title: HF-22061-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22061-(1)


title: HF-23246-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23246-(1)


title: HF-23749-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23749-(1)


title: HF-22122-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22122-(1)


title: HF-22111-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22111-(1)


title: HF-20252-(2)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20252-(2)


title: HF-22048-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22048-(1)


title: HF-23261-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23261-(1)


title: HF-22033-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22033-(1)

value: HR+

source_name: male genomic DNA


title: HF-22064-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22064-(1)


title: HF-21780-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21780-(1)


title: HF-20233-(2)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20233-(2)


title: HF-23747-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-23747-(1)


title: HF-21777-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21777-(1)


title: HF-21772-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21772-(1)


title: HF-22042-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22042-(1)


title: HF-22038-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22038-(1)


title: HF-21819-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21819-(1)


title: HF-21738-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21738-(1)


title: HF-21788-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21788-(1)


title: HF-21824-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21824-(1)


title: HF-21771-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21771-(1)


title: HF-21818-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21818-(1)


title: HF-21827-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21827-(1)


title: HF-21806-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21806-(1)


title: HF-21820-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21820-(1)

source_name: male genomic DNA


title: HF-21773-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21773-(1)


title: HF-21731-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21731-(1)


title: HF-21812-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21812-(1)


title: HF-21761-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21761-(1)


title: HF-22032-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22032-(1)


title: HF-21793-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21793-(1)


title: HF-21732-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21732-(1)


title: HF-21803-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21803-(1)


title: HF-22083-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-22083-(1)


title: HF-21750-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21750-(1)


title: HF-21735-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21735-(1)


title: HF-22799-(1)

description: Tumor vs. Normal.

source_name: prostate cancer, HF-22799-(1)


title: HF-21733-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21733-(1)


title: HF-21800-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21800-(1)


title: HF-21748-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21748-(1)


title: HF-21758-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21758-(1)


title: HF-21753-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21753-(1)

source_name: male genomic DNA


title: HF-21749-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21749-(1)


title: HF-21778-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21778-(1)


title: HF-21769-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21769-(1)


title: HF-21825-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21825-(1)


title: HF-21736-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21736-(1)


title: HF-21817-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21817-(1)


title: HF-21811-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21811-(1)


title: HF-20562-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20562-(1)


title: HF-21795-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21795-(1)


title: HF-21794-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21794-(1)


title: HF-20579-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20579-(1)


title: HF-21781-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21781-(1)


title: HF-20599-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20599-(1)


title: HF-20569-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20569-(1)


title: HF-20590-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20590-(1)


title: HF-20557-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20557-(1)


title: HF-20566-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20566-(1)

source_name: male genomic DNA


title: HF-21744-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21744-(1)


title: HF-21797-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21797-(1)


title: HF-20593-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20593-(1)


title: HF-21745-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21745-(1)


title: HF-20580-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20580-(1)


title: HF-20574-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20574-(1)


title: HF-20582-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20582-(1)


title: HF-21743-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21743-(1)


title: HF-20544-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20544-(1)


title: HF-21741-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21741-(1)


title: HF-20558-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20558-(1)


title: HF-20549-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20549-(1)


title: HF-20543-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20543-(1)


title: HF-20538-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20538-(1)


title: HF-20533-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20533-(1)


title: HF-20534-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20534-(1)


title: HF-20524-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20524-(1)

source_name: male genomic DNA


title: HF-20556-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20556-(1)


title: HF-20535-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20535-(1)


title: HF-20603-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20603-(1)


title: HF-20528-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20528-(1)


title: HF-20598-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20598-(1)


title: HF-20548-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20548-(1)


title: HF-20581-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20581-(1)


title: HF-21019-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21019-(1)


title: HF-21017-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21017-(1)


title: HF-19243-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19243-(1)


title: HF-20525-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20525-(1)


title: HF-20713-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20713-(1)


title: HF-20531-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20531-(1)


title: HF-20621-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20621-(1)


title: HF-20597-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20597-(1)


title: HF-20589-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20589-(1)


title: HF-20260-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20260-(1)

source_name: male genomic DNA


title: HF-20709-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20709-(1)


title: HF-20620-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20620-(1)


title: HF-20828-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20828-(1)


title: HF-17478-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-17478-(1)


title: HF-21047-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21047-(1)


title: HF-17482-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-17482-(1)


title: HF-21013-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21013-(1)


title: HF-20280-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20280-(1)


title: HF-20617-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20617-(1)


title: HF-21045-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21045-(1)


title: HF-21011-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21011-(1)


title: HF-20276-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20276-(1)


title: HF-19275-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19275-(1)


title: HF-20527-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20527-(1)


title: HF-20279-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20279-(1)


title: HF-21040-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-21040-(1)


title: HF-20256-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20256-(1)

source_name: male genomic DNA


title: HF-20278-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20278-(1)


title: HF-20248-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20248-(1)


title: HF-20242-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20242-(1)


title: HF-20228-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20228-(1)


title: HF-20218-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20218-(1)


title: HF-20223-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20223-(1)


title: HF-20219-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20219-(1)


title: HF-20190-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20190-(1)


title: HF-20241-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20241-(1)


title: HF-20244-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20244-(1)


title: HF-20231-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20231-(1)


title: HF-20213-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20213-(1)


title: HF-11368-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11368-(1)


title: HF-20186-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20186-(1)


title: HF-11366-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11366-(1)


title: HF-11375-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11375-(1)


title: HF-20198-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20198-(1)

source_name: male genomic DNA


title: HF-20196-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20196-(1)


title: HF-20192-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20192-(1)


title: HF-19168-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19168-(1)


title: HF-11367-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11367-(1)


title: HF-11377-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11377-(1)


title: HF-20193-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20193-(1)


title: HF-20216-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20216-(1)


title: HF-20214-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20214-(1)


title: HF-20206-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20206-(1)


title: HF-20217-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20217-(1)


title: HF-20209-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20209-(1)


title: HF-20205-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20205-(1)


title: HF-11364-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11364-(1)


title: HF-11372-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11372-(1)


title: HF-19164-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19164-(1)


title: HF-19160-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19160-(1)


title: HF-19152-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19152-(1)

source_name: male genomic DNA


title: HF-19150-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19150-(1)


title: HF-19144-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19144-(1)


title: HF-19158-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19158-(1)


title: HF-18977-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-18977-(1)


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 1600 microM with haploids

status: Public on Jul 26 2010

city: Baltimore

first: Daniel

last: Yuan

address: 733 N. Broadway, Suite 351

department: Molecular Biology and Genetics

institute: Johns Hopkins Univ School of Medicine

description: cells were obtained as a pool of heterozygous diploid yeast knockout strains that were sporulated and selected to yield mata haploid progeny. the parental strain was by4743 (from s288c), with modifications resulting in the following genotype: MATa/alpha ura3delta0 leu2delta his3delta1 lys2delta0/LYS2 met15delta0/MET15 can1delta::LEU2-MFA1pr-HIS3/CAN1 xxx::kanMX/XXX. See PubMed IDs 9483801 (BY4743), 10436161 (xxx::kanMX), 11743205 (MFA1pr), 15525520 (can1, TEF1pr-URA3, selection).

hyb_protocol: Labeled extracts were hybridized overnight to microarray slides at 42 degrees C. See PubMed ID 15994458.

scan_protocol: Images were acquired with a GenePix 4000B scanner.

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 0.67 and 0.84 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

source_name: Control

label_protocol: UpTag and DnTag sequences were amplified from genomic DNA by asymmetric PCR using labeled primers. See PubMed ID 15994458.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates without sodium arsenite. The aliquots of cells used for the two channels were split from the same source and were grown concurrently. See PubMed ID 15525520.

extract_protocol: Genomic DNA was prepared by extraction with phenol-chloroform and ethanol-precipitated. See PubMed ID 15525520.

tag: yko mutant pool

value: haploid

source_name: Experimental

label_protocol: As in Channel 1.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 1600 micromolar sodium arsenite. See PubMed ID 15525520.

extract_protocol: As in Channel 1.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 400 microM with haploids

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 1.98 and 1.78 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 400 micromolar sodium arsenite. See PubMed ID 15525520.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 0 microM with het_dip

description: cells were obtained as a pool of heterozygous diploid yeast knockout strains that were inoculated directly into growth medium. the parental strain was by4743 (from s288c), with modifications resulting in the following genotype: MATa/alpha ura3delta0 leu2delta his3delta1 lys2delta0/LYS2 met15delta0/MET15 can1delta::LEU2-MFA1pr-HIS3/CAN1 xxx::kanMX/XXX. See PubMed IDs 9483801 (BY4743), 10436161 (xxx::kanMX), 11743205 (MFA1pr), 15525520 (can1, TEF1pr-URA3, selection).

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 1.9 and 1.48 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C for 10 generations in YPD liquid medium without sodium arsenite. The aliquots of cells used for the two channels were split from the same source and were grown concurrently. See PubMed ID 15525520.

value: heterezygous diploid

growth_protocol: Cells were grown at 30 degrees C for 10 generations in YPD liquid medium supplemented with 0 micromolar sodium arsenite. See PubMed ID 15525520.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 5 microM with pfd1

description: cells were obtained as a pool of heterozygous diploid yeast knockout strains that were transformed en masse with a pfd1: :TEF1pr-URA3 disruption construct. The resulting double heterozygous mutants were sporulated and selected to yield MATa haploid progeny. The parental strain was BY4743 (from S288C), with modifications resulting in the following genotype: MATa/alpha ura3delta0 leu2delta his3delta1 lys2delta0/LYS2 met15delta0/MET15 can1delta::LEU2-MFA1pr-HIS3/CAN1 xxx::kanMX/XXX. See PubMed IDs 9483801 (BY4743), 10436161 (xxx::kanMX), 11743205 (MFA1pr), 15525520 (can1, TEF1pr-URA3, selection).

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 1.07 and 0.92 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates containing uracil and lacking sodium arsenite. The aliquots of cells used for the two channels were split from the same source and were grown concurrently. See PubMed ID 15525520.

value: null mutation of the prefoldin gene PFD1

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates lacking uracil and supplemented with 5 micromolar sodium arsenite. See PubMed ID 15525520.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 800 microM with haploids

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 2.18 and 1.83 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 800 micromolar sodium arsenite. See PubMed ID 15525520.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 0 microM with haploids

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 2.34 and 1.91 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 0 micromolar sodium arsenite. See PubMed ID 15525520.


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 100 microM with haploids

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 2.27 and 1.76 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 100 micromolar sodium arsenite. See PubMed ID 15525520.


title: HF-18971-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-18971-(1)


title: HF-11349-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11349-(1)


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 200 microM with haploids

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 2.61 and 1.57 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C to confluence on "Magic Marker" selection plates supplemented with 200 micromolar sodium arsenite. See PubMed ID 15525520.


title: HF-11345-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11345-(1)


title: HF-18958-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-18958-(1)


title: HF-11239-(2)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11239-(2)


title: Trivalent arsenic inhibits the functions of chaperonin complex: Sodium arsenite 450 microM with het_dip

data_processing: Two-channel image files were analyzed with the GenePix Pro software package (Molecular Dynamics, version 5.1). Median intensities were used to subtract background from foreground values. The only features considered were those with ID_REF within the ranges 1:6018 (for UpTags) or 10972:16989 (for DnTags). Ratios of the background-corrected 635nm to 532nm values were obtained. Ratios were ignored when foreground control values (F635) were less than 400. UpTag and DnTag ratios were multiplied by the normalization factors 2.34 and 1.82 (respectively). These normalization factors were obtained by dividing (a) the sum of F532 values over all features considered for the given tag type by (b) the corresponding sum of F635 values. For log2 transformed results, background-corrected experimental (532 nm) values below 3*sqrt(B532) were coerced to this threshold.

growth_protocol: Cells were grown at 30 degrees C for 10 generations in YPD liquid medium supplemented with 450 micromolar sodium arsenite. See PubMed ID 15525520.


title: HF-11326-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11326-(1)


title: PE763T

status: Public on Jul 19 2010

city: Chapel Hill

first: Jen Jen

last: Yeh

state: NC

address: LCCC, 450 West Drive

department: Surgical Oncology

institute: University of North Carolina at Chapel Hill

description: Pancreatic Tumor. T Stage: 2, N Stage/Nodal status: positive(1 or more nodes), Risk Group: High Risk

hyb_protocol: As described in Agilent Two-Color Microarray-Based Gene Expression Analysis (Quick Amp labeling) v 5.7 [Manual G4140-90050]

scan_protocol: Fluorescent array images were collected for both Cy3 and Cy5 with an Agilent G2505C fluorescent scanner and image intensity data were extracted and analyzed with Agilent Feature Extraction (v10.5) software.

data_processing: Data for both channels were Lowess-normalized and then log(2) ratio was taken using Agilent Feature Extraction (v10.5) software.

source_name: Human Reference

extract_protocol: Total RNA isolated by Qiagen

value: Stratagene Human reference RNA

source_name: Pancreas Tissue

extract_protocol: Qiagen Rneasy Kit

tag: os time

tag: os event

tag: t stage

tag: n stage

value: Patient Primary Pancreatic Tumor

tag: risk group

value: High Risk


title: PE741T

description: Pancreatic Tumor. T Stage: 3, N Stage/Nodal status: positive(1 or more nodes), Risk Group: High Risk

label_protocol: As described in Agilent Two-Color Microarray-Based Gene Expression Analysis (Quick Amp labeling) v 5.7 [Manual G4140-90050]


title: PE751T

description: Pancreatic Tumor. T Stage: 3, N Stage/Nodal status: positive(1 or more nodes), Risk Group: Low Risk

value: Low Risk


title: PE718T


title: HF-18993-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-18993-(1)

tag: gender

value: reference


title: HF-11217-(6)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11217-(6)


title: PE716T


title: HF-19142-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-19142-(1)

source_name: male genomic DNA


title: PE715T


title: HF-20238-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-20238-(1)


title: HF-18964-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-18964-(1)


title: HF-11241-(6)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11241-(6)


title: PE548T


title: PE704T


title: PE621T

description: Pancreatic Tumor. T Stage: 2, Risk Group: High Risk

tag: n stage:


title: PE545T

description: Pancreatic Tumor. T Stage: 3, N Stage/Nodal status: negative, Risk Group: High Risk


title: P63T

description: Pancreatic Tumor. T Stage: 2, N Stage/Nodal status: negative, Risk Group: Low Risk


title: PE323T

description: Pancreatic Tumor. T Stage: 2, N Stage/Nodal status: negative, Risk Group: High Risk


title: PE319T


title: PE299T


title: P92T


title: PE402T


title: PE133T


title: P35T

description: Pancreatic Tumor. , N Stage/Nodal status: positive(1 or more nodes), Risk Group: High Risk

tag: t stage:


title: HF-11313-(1)

description: Tumor vs. Normal.

source_name: breast cancer, HF-11313-(1)


title: PE701T


title: P41T Replicate


title: PE215T


title: P85T


title: PE734T

description: Pancreatic Tumor. , N Stage/Nodal status: positive(1 or more nodes), Risk Group: Low Risk

tag: tumor type

value: Pancreatic Tumor


title: P40T


title: P42T

description: Pancreatic Tumor. , N Stage/Nodal status: negative, Risk Group: High Risk


title: P268T


title: P275T Replicate

description: Pancreatic Tumor. T Stage: 3, N Stage/Nodal status: negative, Risk Group: Low Risk


title: P31T Replicate


title: P249T


title: PE182T


title: P272T


title: P260T


title: P248T


title: P245T


title: P258T


title: P237T


title: P227T


title: P214T


title: P174T


title: P242T


title: P194T


title: P190T


title: P147T


title: P182T


title: P180T Replicate


title: P152T

description: Pancreatic Tumor. , N Stage/Nodal status: negative, Risk Group: Low Risk

value: Pancreatic Tumor.


title: P183T


title: P178T


title: P188T IPMN

description: Pancreatic Tumor. T Stage: 1, N Stage/Nodal status: positive(1 or more nodes), Risk Group: High Risk


title: P148T


title: P139T


title: P162T


title: P138T

description: Pancreatic Tumor. T Stage: 1, N Stage/Nodal status: negative, Risk Group: Low Risk


title: P128T


title: P131T


title: P164T redo


title: P235T


title: P124T


title: P184T


title: P146T


title: P130T


title: P110T


title: P120T


title: P112T


title: P122T


title: P271N Replicate


title: PH765T


title: P109T


title: PH41130T


title: PH8942T


title: PH37202T


title: PH3939T


title: PH39655T


title: PH376T

description: Pancreatic Tumor. T Stage: 2, N Stage/Nodal status: positive(1 or more nodes), Risk Group: Low Risk


title: PH36746T


title: PH32757T


title: PH33566T


title: PH35398T


title: PH25396T


title: PH23822T


title: P241T


title: PH35636T


title: PH3032T


title: PH42166T


title: PH21935T


title: PH21887T


title: PH22143T


title: PH27238T


title: PH20548T


title: PH19770T


title: PH20852T


title: PH19267T


title: PH19682T


title: PH35343T


title: PH22420T

description: Pancreatic Tumor. T Stage: 4, N Stage/Nodal status: positive(1 or more nodes), Risk Group: High Risk


title: PH10162T


title: PH17803T


title: P06-1118B


title: PH11632T


title: PH06-12553T


title: 7R1353

description: 7R1353Brpt Panc 70/30/0


title: 9R1701B

description: 9R1701B Mix Panc (10/90/0)


title: P071118B


title: P99-0320B


title: PH16649T


title: P06-1552B


title: 9R1701.2

description: 9R1701.2P Mix


title: 143B TK-ρ+_rep1

status: Public on Jul 17 2010

city: seoul

first: hyun-jung

last: koo

address: hoegi-dong,dongdaemun-gu

country: South Korea

institute: Kyung Hee University

description: replicate 1

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: The data were normalized using quantile normalization using the Avadis 4.3 software (Strand Genomics).

source_name: bone

label_protocol: Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays

growth_protocol: The cells were cultured in high glucose (4.5g/L) DMEM supplemented with 10% fetal bovine serum (FBS), antibiotics (100 µg/ml penicillin/streptomycin mix), and uridine (50 µg/ml) in a humidified atmosphere at 37℃ with 5% CO₂ .

extract_protocol: Total RNA from ρ+ or ρ0 cells (n=3) was isolated using TRIzol (Invitrogen, Karlsruhe, Germany) and quantified with NanoDrop spectrophotometer (NanoDrop Technologies, Inc.).

value: bone

tag: disease

value: osteosarcoma

tag: cell type


title: 4R678B2

description: 4R678B2 Mix Panc

value: 4R678B2 Mix Panc


title: 5R913

description: 5R913Mix Pancreas 50/30/20

value: 5R913Mix Pancreas 50/30/20


title: P071155B


title: P070710B


title: PH15861T


title: 3R261B

description: 3R261B T Panc

value: 3R261B T Panc


title: 2R14B

description: 2R14B Mix Pancreas (KV:Tu in LN) 30/60/10


title: 12R2587.1

description: 12R2587.1Mix(50%N) P


title: 12R2685T

description: 12R2685T Panc

value: 12R2685T Panc


title: 13R2778

description: 13R2778 Mix(90%N) Panc


title: 12R2585B

description: 12R2585B Mix Pancreas (20/80/0)


title: 9R1703

description: 9R1703Mix Pancreas

value: 9R1703Mix Pancreas


title: 12R2587.2

description: 12R2587.2Mix(80%N) P


title: 8R1405

description: 8R1405Mix 20/60/20


title: PH17733T


title: P06-1366B


title: shet169 | t(6;9)

status: Public on Jul 11 2010

city: Berlin

first: Lars

last: Bullinger

address: Augustenburger Platz 1

department: Hematology, Oncology and Tumorimmunology

institute: Charité

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47473.gif

hyb_protocol: not provided

scan_protocol: GenePix 4000B

data_processing: VALUE is Log (base 2) of the ratio of the median of Channel 2 (usually 635 nm) to Channel 1 (usually 532 nm)

source_name: Stratagene common reference

extract_protocol: not provided

tag: reference

value: Stratagene common reference

label_protocol: RNA from AML specimens was labeled with Cy5-dUTP using an anchored poly(dT) primer during first strand reverse transcription (Superscript II).  A universal reference RNA (pooled from 11 cell lines) was labeled identically but with Cy3-dUTP

extract_protocol: Normal karyotype acute myeloid leukemia (NK-AML) specimens comprise Ficoll gradient purified mononuclear cells (>80% blasts) from diagnostic peripheral blood or bone marrow.  Total RNA was isolated from stored, frozen mononuclear AML-cell pellets using Trizol reagent, and RNA quality assessed by gel electrophoresis.; Protocol Type = Extract preparation

tag: source

tag: age

tag: overall survival time

value: 125 days

tag: overall survival status

value: dead

tag: genotype

value: female


title: shet170 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47474.gif

label_protocol: A universal reference RNA (pooled from 11 cell lines) was labeled identically but with Cy3-dUTP

source_name: 01KM632; Sample source=BM; CBF group=t(8;21)

value: 446 days

value: other

value: male


title: shfe229 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-07/62746.gif

value: 368 days

value: normal karyotype


title: shee128 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42879.gif

value: 75 days


title: shet120 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47460.gif

value: 112 days


title: shee156 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/43269.gif

value: 29 days


title: shee158 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/43404.gif

value: 54 days


title: shet135 | t(9;11)

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47462.gif

value: 814 days


title: shee230 | complex karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-08/44175.gif

value: 83 days

value: complex karyotype


title: shee081 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42651.gif

value: 20 days


title: shet185 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47480.gif

value: Stratagene common reference

value: 35 days


title: shee083 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42654.gif

value: 15 days

value: dead


title: shee120 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42876.gif

value: 22 days


title: shet121 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47461.gif

value: 526 days

value: other

value: female


title: shfe016 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-08/63000.gif

value: 387 days

value: normal karyotype

value: male

tag: runx1 mutation


title: shee070 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42650.gif

value: 2985 days

value: alive


title: shee068 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42648.gif

value: 737 days


title: shee085 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42745.gif

value: 109 days


title: shee082 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42652.gif

value: 218 days


title: shee067 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42647.gif

value: 3211 days


title: shee149 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/43267.gif

value: Stratagene common reference

value: 518 days


title: shet030 | t(15;17)

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47444.gif

value: 49 days


title: shee157 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/43403.gif

value: 192 days

value: dead


title: shee147 | t(15;17)

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/43265.gif

value: 1986 days


title: shee096 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42746.gif

value: 305 days


title: shee220 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-08/44118.gif

value: 81 days

value: female


title: shet172 | t(8;21)

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-12/47476.gif

source_name: 01PB1332; Sample source=PB; CBF group=t(8;21)

value: 1447 days


title: shee069 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42649.gif

value: 3246 days

value: normal karyotype


title: shee084 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42655.gif

value: 70 days


title: shdj065 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/32814.gif

source_name: AML 39

value: AML 39

value: 151 days


title: shee127 | del(7q)/-7

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-07/42878.gif

value: 434 days


title: shdj092 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/33492.gif

source_name: AML 75

value: AML 75

value: 513 days

value: other

value: male


title: shee170 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2003-08/43795.gif

value: Stratagene common reference

value: 3 days


title: shfs124 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-05/61362.gif

value: 415 days

value: dead


title: shco040 | t(8;21)

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-04/28221.gif

source_name: AML 26; Sample source=PB; CBF group=t(8;21)

value: 162 days


title: shgn114 | complex karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2006-01/66434.gif

value: 557 days

value: alive

value: complex karyotype

value: female


title: shdj087 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/33362.gif

source_name: AML 54

value: AML 54

value: 353 days


title: shgn89 | complex karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-12/66089.gif

value: 119 days


title: shdj093 | complex karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/33496.gif

source_name: AML 72

value: AML 72

value: 300 days


title: shfs081 | del(7q)/-7

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-02/59324.gif

value: 1083 days


title: shdj074 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/33063.gif

source_name: AML 91

value: AML 91

value: 95 days

value: normal karyotype


title: shgn143 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2006-01/66439.gif

value: Stratagene common reference

value: 153 days

value: other


title: shgn112 | complex karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2006-01/66244.gif

value: 32 days

value: dead


title: shdj082 | normal karyotype

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2002-09/33165.gif

source_name: AML 93

value: AML 93

value: 206 days

value: male


title: shfs101 | other

description:
Simple annotation: Myeloid Leukemias, Acute Myeloid Leukemia
Image: http://smd.stanford.edu/MicroArray/gifs/2005-03/60251.gif

tag: disease state time

value: PTD